TSE:CUR 45525 (CUR.TO) (CUR) Stock Price, News & Analysis → [Shocking] Elon Musk’s Plan To End Banks (From Crypto 101 Media) (Ad) Free CUR Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume130,253 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetC$3.00 Stock AnalysisStock Analysis Get 45525 (CUR.TO) alerts: Email Address Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About 45525 (CUR.TO) Stock (TSE:CUR)9342-8530 Quebec Inc, formerly Diagnocure Inc, is a Canada-based biotechnology company. The Company specializes in the development and commercialization of products relating to the diagnosis of cancer. It intends to focus its activities on business development efforts by out-licensing, selling or partnering with third parties with regards to its Previstage GCC and its new multimarker prostate cancer test (PCP). The Company's colorectal cancer staging test, Previstage GCC, uses the Guanylyl Cyclase C (GCC or GUCY2C) marker to stratify the risk of colon cancer recurrence by determining the stage of the disease. Previstage GCC Colorectal Cancer Staging test is a molecular test for the staging of colorectal cancer patients. The PROGENSA PCA3 assay is a molecular urine test that can be used as a predictor of biopsy outcome in men with a serum prostate specific antigen (PSA) level over 2.5 nanograms per milliliter (ng/ml).Read More Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… CUR Stock News HeadlinesJanuary 30, 2024 | dailymail.co.ukCould this pill cure sunburn?January 7, 2024 | money.usnews.com10 of the Best Stocks to Buy for 2024April 23, 2024 | Crypto 101 Media (Ad)[Shocking] Elon Musk’s Plan To End BanksLeaked Elon Musk call reveals shocking plan to replace banks. As Musk's plan rolls out, industry experts predict it could spark a wave of mass crypto adoption. Triggering a new crypto bull run. While helping drive a booming crypto asset class up from $2.5-billion to $16-trillion (a 6,400x increase) by 2030. December 14, 2023 | fool.comBest Stocks to Buy in December 2023August 9, 2023 | dailymail.co.ukHow to conquer fear of flying - I'm a frequent flyer and these are the best ways to cure aerophobiaJuly 28, 2023 | dailymail.co.ukIs there a natural cure for psoriasis?June 30, 2023 | forbes.comHow To ‘Cure’ A Hangover: Expert-Backed Ways To Ease SymptomsApril 29, 2023 | nypost.comI tried TikTok’s ‘sleepy girl mocktail’ to cure insomnia — then this happenedApril 23, 2024 | Crypto 101 Media (Ad)[Shocking] Elon Musk’s Plan To End BanksLeaked Elon Musk call reveals shocking plan to replace banks. As Musk's plan rolls out, industry experts predict it could spark a wave of mass crypto adoption. Triggering a new crypto bull run. While helping drive a booming crypto asset class up from $2.5-billion to $16-trillion (a 6,400x increase) by 2030. April 13, 2023 | forbes.comHerbs To Cure Your Prostate Problems? I Don’t Think SoApril 8, 2023 | usatoday.comThe Cure's Robert Smith says Ticketmaster to issue tour ticket fee refunds: 'Sickened'April 3, 2023 | dailymail.co.ukCure for Alzheimer's closerMarch 25, 2023 | seekingalpha.comXPDUSD:CUR Palladium FuturesMarch 20, 2023 | nypost.comI’m a psychotherapist — here’s how to cure the ‘Sunday scaries’February 27, 2023 | thetimes.co.ukTHG needs to swallow Matt Moulding’s coffee cureFebruary 17, 2023 | cnbc.comCharlie Munger weighs in on ChatGPT3: Artificial intelligence is not going to cure cancerFebruary 16, 2023 | benzinga.comCURE ALZHEIMER'S FUND APPOINTS DRS. JOHN S. LAZO AND PATRICK C. MAY TO RESEARCH STRATEGY COUNCILFebruary 8, 2023 | dailymail.co.ukPill to cure baldnessJanuary 25, 2023 | dailymail.co.ukWould YOU take pills made from someone else poop to cure a nasty gut infectionJanuary 22, 2023 | dailymail.co.ukIs the viral TikTok hangover cure the real deal? Submerging your face in a bowl of ice water is only a short-term trick- and some doctors warn 'not to try it at home'January 15, 2023 | yahoo.com'Top Chef' Melissa King shares how to cure fish at home: 'fascinating and quite easy'October 17, 2022 | time.comDoctors in India Tried to ‘Cure’ Her With Conversion Therapy. Now She’s Fighting to Ban ItOctober 13, 2022 | cnbc.comDoes a $0 balance on your credit card make your score go up?October 6, 2022 | money.usnews.comDivided European Aviation Sector Seeks Cure to Travel ChaosJune 13, 2022 | finance.yahoo.comGuerbet receives EMA acceptance of EluciremTM as the Brand Name for GadopiclenolSee More Headlines Receive CUR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 45525 (CUR.TO) and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolTSE:CUR CUSIPN/A CIKN/A Webwww.neuralstem.com Phone+1-418-5276100FaxN/AEmployees6Year FoundedN/APrice Target and Rating Average Stock Price TargetC$3.00 High Stock Price TargetC$3.00 Low Stock Price TargetC$3.00 Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key CompetitorsCanada House Wellness GroupCNSX:CHVDirexion Daily Healthcare Bull 3X SharesCNSX:CUREMatica EnterprisesCNSX:MMJPreveCeutical MedicalCNSX:PREVSonicShares Airlines, Hotels, Cruise Lines ETFCNSX:TRYPView All Competitors CUR Stock Analysis - Frequently Asked Questions Should I buy or sell 45525 (CUR.TO) stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for 45525 (CUR.TO) in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CUR shares. View CUR analyst ratings or view top-rated stocks. What is 45525 (CUR.TO)'s stock price target for 2024? 1 analysts have issued twelve-month price objectives for 45525 (CUR.TO)'s stock. Their CUR share price targets range from C$3.00 to C$3.00. On average, they anticipate the company's stock price to reach C$3.00 in the next year. View analysts price targets for CUR or view top-rated stocks among Wall Street analysts. What other stocks do shareholders of 45525 (CUR.TO) own? Based on aggregate information from My MarketBeat watchlists, some companies that other 45525 (CUR.TO) investors own include Soleno Therapeutics (SLNO), Adverum Biotechnologies (ADVM), Adient (ADNT), Adaptimmune Therapeutics (ADAP), AcelRx Pharmaceuticals (ACRX), Aclaris Therapeutics (ACRS), ACM Research (ACMR), Achillion Pharmaceuticals (ACHN), ACADIA Pharmaceuticals (ACAD) and Arbutus Biopharma (ABUS). How do I buy shares of 45525 (CUR.TO)? Shares of CUR stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:CUR) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 45525 (CUR.TO) Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
